Key result
Amniotic fluid NT-proBNP concentrations were significantly higher in fetuses with congenital heart defects or arrhythmias compared to controls (97.2 vs 40.9 pg/mL) and increased stepwise with the severity of fetal heart failure.
Why the study?
Do amniotic fluid natriuretic peptide levels correlate with the severity of heart failure in fetuses with congenital heart defects or arrhythmias?
Observational (n=191)
No
Do amniotic fluid natriuretic peptide levels correlate with the severity of heart failure in fetuses with congenital heart defects or arrhythmias?
Absolute Event Rate: 97.2% vs 40.9%
p-value: p=0.01
Amniotic fluid NT-proBNP concentrations increase in a stepwise fashion with the severity of fetal heart failure, making it a useful biomarker for assessing heart failure in fetuses with congenital heart defects or arrhythmias.
AF NP levels may support noninvasive fetal HF assessment in CHD/arrhythmia; leaves open need for validation before clinical adoption.
BACKGROUND: We have previously demonstrated that umbilical cord plasma natriuretic peptide (NP) levels reflect the severity of heart failure (HF) in fetuses with congenital heart defects (CHD). The aim of this study was to evaluate the significance of amniotic fluid (AF) NP levels in the assessment of HF in fetuses with CHD or arrhythmia. METHODS AND RESULTS: This was a prospective observational study at a tertiary pediatric cardiac center. A total of 95 singletons with CHD or arrhythmia, and 96 controls from 2012 to 2015 were analyzed. AF concentrations of atrial NP (ANP), B-type NP (BNP) and N-terminal pro-B-type NP (NT-proBNP) at birth were compared with ultrasonographic assessment of fetal HF using the cardiovascular profile (CVP) score. Multivariate analysis showed that a CVP score ≤5 and preterm birth are independently associated with high AF NT-proBNP levels. AF NT-proBNP levels of fetuses with CHD or arrhythmia inversely correlated with CVP score (P for trend <0.01). In contrast, AF concentrations of ANP and BNP were extremely low, and it was difficult to assess the degree of fetal HF based on them. CONCLUSIONS: AF NT-proBNP concentrations increase in stepwise fashion with the severity of HF in fetuses with CHD or arrhythmia; it was the optimal NP for assessing the fetal HF.
No takes yet. Share an insight, caveat, or question.
Miyoshi et al. (2018) conducted an observational in Congenital heart defects or arrhythmias in fetuses (n=191). Congenital heart defects or arrhythmias vs. Healthy control fetuses was evaluated on Amniotic fluid NT-proBNP levels (pg/mL) (p=0.01). Amniotic fluid NT-proBNP concentrations were significantly higher in fetuses with congenital heart defects or arrhythmias compared to controls (97.2 vs 40.9 pg/mL) and increased stepwise with the severity of fetal heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: